Clinical Trial Update: A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label study evaluating MEDI0680 (AMP-514) with durvalumab vs nivolumab monotherapy in select advanced malignancies, including kidney cancer and c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Kidney Cancer
• Select Advanced Malignancies

Drugs mentioned

• Durvalumab (durvalumab)
• MEDI0680 (AMP-514) (medius0680? (AMP-514))
• nivolumab (nivolumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Select Advanced Malignancies, Kidney Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-01